Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 10/20 | 0.74 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17424035 | 0.94 | GNAO1 (0.67) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| SCHEMBL7733753 | 0.92 | GNAO1 (0.70) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| SCHEMBL25121970 | 0.92 | GNAO1 (0.70) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| SCHEMBL25444591 | 0.92 | GNAO1 (0.70) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL30330544 | 0.92 | GNAO1 (0.70) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL30330575 | 0.90 | GNAO1 (0.73) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Fluoride SCHEMBL29252068 | 0.90 | GNAO1 (0.68) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Fluoride SCHEMBL29252689 | 0.90 | GNAO1 (0.68) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Fluoride SCHEMBL31318598 | 0.90 | GNAO1 (0.68) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Fluoride SCHEMBL29252484 | 0.90 | GNAO1 (0.68) | GNAO1GNAI3GNAI1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021163339-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (US) | 2021-08-19 | — | — | WO | disclosed |